The pharmaceutical company in Biotech Center @Sahlgrenska SP has developed a platform technology for the treatment of autoimmune diseases. The technology enables the production of drugs that target the cause of the disease – not just the symptoms, which is currently the common treatment. The main project is aimed at an autoimmune nerve muscle disease, myasthenia gravis, for which there is a great need for improved medical treatment.
“We are very happy to have been selected to receive funding from Swelife, which is an important recognition for the TOL2 project,” says Charlotte Fribert, CEO of Toleranzia, in a press release.
Through this financing, the company will be able to validate the process on a larger scale and produce materials for the development of the formulation of TOL 2 for clinical studies.
Recently, positive, preliminary results were also presented from a toxicological study with TOL2, which was carried out in collaboration with RISE, which Nyhetsbyrån Direkt reported on.
LEARN MORE: Impatient industry to Löfven: appoint a minister for life science
LEARN MORE: Six mega trends in Sahlgrenska Science Park report
LEARN MORE: Toleranzia erhåller finansiering från Swelife för samarbete med Testa Center
Photo of Charlotte Fribert, CEO, Toleranzia. She is one of the members of our CEO network @Sahlgrenska SP.
LEARN MORE: VD-klubben @Sahlgrenska SP
Sahlgrenska Science Park is the West Swedish coordinator for Swelife and new calls will be presented on our site.